The study involved two major activities in estimating the current market size of the human microbiome market. Exhaustive research was conducted to collect information on the market as well as its peer and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.
The global human microbiome market is projected to reach USD 1,731 million in 2027 from USD 942 million in 2024, at CAGR of 22.5 % during the forecast period. Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is expected to offer a wide range of growth opportunities for market players during the forecast period. However, a lack of expertise and detailed research on the human microbiome is restraining the growth of this market.
Download PDF Brochure@
Key questions addressed by the report:
# Who are the major market players in the human microbiome market?
# What are the regional growth trends and the largest revenue-generating regions for the market?
# What are the major drivers and challenges in the market?
# What are the major product segments in the market?
# What are the major technologies used in the human microbiome research spending market?
The probiotics segment to account for the largest share of the global human microbiome market in 2022
Based on product, the human microbiome market is segmented into probiotics, prebiotics, foods, medical foods, diagnostic tests, and drugs. The probiotics segment is expected to account for the largest share of the human microbiome market in 2022. The increasing awareness of probiotics for the prevention and treatment of various lifestyle & chronic diseases and health benefits of probiotics over conventional medicines, such as antibiotics are some of the major factors driving the growth of this segment.
The therapeutics segment to account for the largest share of the market in 2022
Based on application, the human microbiome market is segmented into therapeutics and diagnostics. The therapeutics segment is expected to dominate the market in 2022. This is due to the need for the development of reliable, precise, and quicker treatment of chronic lifestyle diseases and various other disorders.
Report Objectives:
# To define, describe, segment, and forecast the market on the basis of product, application, disease, technology, and region
# To define, describe, segment, and forecast the human microbiome research spending market on the basis of technology
# To provide detailed information about the factors influencing market growth (drivers, restraints, opportunities, and challenges)
# To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
# To forecast the size of market segments with respect to four main regions (along with countries), namely, North America, Europe, the Asia Pacific (APAC), and the Rest of the World (RoW)
# To profile key players and comprehensively analyze their core competencies in terms of key developments, product portfolios, and financials
# To track and analyze competitive developments such as acquisitions; partnerships, agreements, & collaborations; product launches; and expansions in the human microbiome market
Request Sample Pages@
The infectious diseases segment to account for the largest share of the market in 2022
Based on disease, the human microbiome market is segmented into five categories—infectious diseases, endocrine & metabolic disorders, inflammatory diseases, cancer, and other diseases. The infectious disease segment is expected to dominate the market in 2022. This is due to the increasing research in microbiome-based products and their use in treating infectious diseases. Many smaller companies are investing in research, and their major focus is on developing products targeting microbiome modulators for infectious diseases.
Europe to account for the largest share of the human microbiome market in 2022
On the basis of region, the global human microbiome market is segmented into four major geographies— North America, Europe, the Asia Pacific, and the Rest of the World (RoW). Europe is expected to account for the largest share of the global human microbiome market in 2022. The large share of this regional segment is mainly due to the high research activity in this region.
Recent Developments:
# In 2019, Seres collaborated with AstraZeneca to get a better understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with AstraZeneca compounds.
# In 2018, Enterome entered into a co-development and co-promotion agreement with Takeda for its investigational drug candidate EB8018. This drug is used in patients with Crohn’s disease and has the potential to expand its use to other gastrointestinal (GI) disorders and liver diseases.
# In 2016, 4D Pharma acquired the production assets of Instituto Biomar to expand its clinical and production capabilities of live biotherapeutics.
The major players in the human microbiome market include Enterome Bioscience (France), E.I. du Pont de Nemours and Company (DuPont) (US), 4D Pharma (UK), and Seres Therapeutics (US). Various growth strategies have been adopted by these players, such as product launches, agreements, and acquisitions to increase their presence in the global human microbiome market.
Feel FREE to Connect to Our Experts@
No comments:
Post a Comment